Gornet, M
Precedent: CagriSema Success Supports Combination Approach The strongest evidence supporting a cagrilintide blend with retatrutide comes from Novo Nordisk's CagriSema program, which combines cagrilintide with semaglutide (a GLP-1 receptor agonist)
Sehgal P, Gupta R, Choudhary K, Singh R BPC 157: A Promising Candidate for Cytoprotection and Tissue Repair
Tesamorelin has shown to decrease carotid intima-media thickness (cIMT), visceral adipose tissue (VAT) and c-reactive protein (CRP.) Although, this growth hormone has not been linked to significantly affect other pituitary hormones and other respective mechanisms of the body
Corticotrophin-releasing factor 1 activation in the central amygdale and visceral hyperalgesia
Disclosure of interest: Helena Aineskog: nothing to disclose Poster Session I - RECOVERY, REHABILITATION AND OUTCOME 03.00 - RECOVERY, REHABILITATION AND OUTCOME - 03.03 - PROGNOSIS AND OUTCOME AFTER STROKE P228 - ESOC25-2239 LEVEL OF COGNITIVE ABILITIES AND THEIR PREDICTORS AMONG INDIVIDUALS WITH STROKE Khader Almhdawi 1 1 Department of rehabilitation Sciences, Jordan University of Science and Technology, Irbid, Jordan Background and Aims: Individuals post-stroke tend to have significant declines in their cognitive abilities which could hinder their functional independence and well-being
